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Abstract
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Mesenchymal stem cells (MSCs) have been used in 
studies on treatment of various diseases, and their application to 
immune-mediated diseases has garnered interest. Various 
methods for enhancing the immunomodulation effect of human 
MSCs have been used; however, similar approaches for canine 
MSCs are relatively unexplored. Accordingly, I evaluated 
immunomodulatory effects and mechanisms in canine MSCs 
treated with TNF-α and IFN-γ. Canine MSCs were stimulated 
with TNF-α and IFN-γ for 24 hours to produce conditioned 
media (CM). Lipopolysaccharide (LPS)-stimulated RAW 264.7 
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cells were co-cultured with the MSCs for 48 h in CM. 
Expression of RNA was assessed by quantitative reverse 
transcription PCR (qRT-PCR), and protein levels were assessed 
by western blot. Expression of inducible nitric oxide synthase 
(iNOS), IL-6 and IL-1β was significantly (one-way ANOVA) 
decreased in LPS-stimulated RAW 264.7 cells co-cultured with 
naïve canine MSCs compared to that in LPS-stimulated RAW 
264.7 cells alone. Furthermore, anti-inflammatory effects of 
TNF-α- and IFN-γ-primed canine MSCs were significantly 
increased compared with those of naïve canine MSCs. Expression 
of cyclooxygenase 2 (COX-2) and prostaglandin E2 (PGE2) 
were likewise significantly increased in primed canine MSCs. The 
level of iNOS protein in LPS-stimulated RAW 264.7 cells 
co-cultured with the primed canine MSCs was decreased, but it 
increased when the cells were treated with NS-398(PGE2 
inhibitor). In conclusion, compared with naïve canine MSCs, cells 
primed with TNF-α and IFN-γ cause a greater reduction in 
release of anti-inflammatory cytokines from LPS-stimulated 
RAW 264.7 cells; the mechanism is upregulation of the 
COX-2/PGE2 pathway.
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Figure 1. Characteristics of MSCs isolated from 
canine adipose tissue and bone marrow.
Figure 2. Anti-inflammatory effects of primed cAT 
and BM-MSCs on LPS-stimulated RAW 
264.7 cells.
Figure 3. Anti-inflammatory effects of primed cAT 
and BM-MSCs on LPS-stimulated cPBMCs.
Figure 4. COX-2 protein level in TNF-α- and 
IFN-γ-primed cMSCs.
Figure 5. Protein level of PGE2 in supernatant of 
TNF-α- and IFN-γ-primed cMSCs.
Figure 6. Changes in the secretion of PGE2 in     
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Mesenchymal stem cells (MSCs) are multipotent cells that 
can be isolated from adipose tissue, bone marrow, umbilical cord 
blood, synovium, dental pulp, and other sources (Al-Nbaheen et 
al., 2013; Ribeiro et al., 2013). MSCs can differentiate into cells 
of connective tissue, bone, fat, cartilage, and muscle. They have 
been isolated from the human, equine, bovine, feline, and canine 
sources (Jacobs et al., 2013; Marx et al., 2015).
Previous studies reported immunomodulatory functions for 
MSCs (Ma et al., 2014; Plock et al., 2014; Shi et al., 2012), and 
MSCs have been used in studies on treatment of 
immune-mediated diseases (Kim et al., 2016; Le Blanc et al., 
2004). For example, human MSCs have been used in research 
on treatment of inflammatory bowel disease, systemic lupus 
erythematosus, graft-host disease, ulcerative colitis, Crohn’s 
disease, multiple sclerosis, autoimmune diabetes, and rheumatoid 
arthritis (Dave et al., 2015; Glenn and Whartenby, 2014). In 
addition, canine MSCs in particular have been used for the 
treatment of inflammatory bowel disease, systemic lupus 
erythematosus, autoimmune diabetes, and perianal fistula (Ferrer 
et al., 2016; Hoffman and Dow, 2016).
Those studies reported that not only do MSCs migrate 
directly to the site of inflammation, but they also exert indirect 
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anti-inflammatory effects through secretory factors (Kang et al., 
2008; Matthay et al., 2010; Song et al., 2017). Human MSCs 
regulate inflammatory processes through various soluble factors 
such as indoleamine 2,3-dioxygenase (IDO), TNF-α-stimulated 
gene-6 (TSG-6), and prostaglandin E2 (PGE2) (Liu et al., 2016; 
Spaggiari et al., 2008). PGE2 and TSG-6 were secreted by 
mouse MSCs (Ghannametal., 2010; Prockop and Oh, 2012), 
where as TSG-6, indoleamine 2,3-dioxygenase (IDO), TGF-β, 
hepatocyte growth factor (HGF), and PGE2 were secreted by 
canine MSCs (Kang et al., 2008).
I have focused on making immunomodulation of MSCs 
more effective. Despite diverse and growing research on 
preconditioning strategies such as stimulation by hypoxia, 
inflammatory stimuli, and activation by three-dimensional culture 
(English et al., 2007; Hemeda et al., 2010; Madrigal et al., 2014; 
Yu et al., 2013), studies on immune regulatory effects of canine 
MSCs are few and have become an active area of investigation. 
Accordingly, I evaluated immunomodulatory effects of canine 
MSCs conditioned with tumor necrosis factor-alpha (TNF-α) 
and interferon-gamma (IFN-γ) and I examined the mechanisms 
by which the immunoregulation is induced.
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2. Material and Methods
2.1. Animals
Stem cells were obtained from three healthy dogs at the 
Seoul National University Veterinary Medicine Teaching Hospital 
(SNU VMTH). The dogs were one to three years old and 
weighed from 7 to 15 kg. The mean body-condition score was 
grade 5. Two dogs were castrated males, and one dog was a 
spayed female. Procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of SNU (IACUC 
approval № SNU-170724-5), and the protocol was performed in 
accordance with approved guidelines.
Dogs were sedated by intravenous injection of 
acepromazine (0.01 mg/kg), and anesthetized with alfaxane (2 
mg/kg). These dogs were intubated, then maintained on 
inhalation anesthesia with isoflurane for cell harvest. Skin and 
subcutaneous tissues were desensitized by local infiltration of 
2% lidocaine (Vieira et al., 2010). A fat sample was aseptically 
collected from the gluteal subcutaneous fat by incising the skin, 
after which sharp and blunt dissection was used to remove the 
fat as previously described (Kang et al., 2012; Kang et al., 
2008). Bone marrow aspirates were aseptically harvested from 
the proximal humerus in a manner similar to that described 
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previously (Lee et al., 2011; Singh et al., 2014; Sullivan et al., 
2015). The bone was palpated, and a small incision was made 
into the skin and subcutaneous tissues. A 12-gage Rosenthal 
needle was inserted, after which a 35-㎖ heparinized syringe 
(1000 IU/㎖ of blood) was used to aspirate bone marrow and 
blood.
2.2. Harvest and isolation of canine adipose-tissue 
-derived mesenchymal stem cells(cAT-MSCs)
Fat samples were washed three times in Dulbecco’s 
phosphate-buffered saline (DPBS; PAN-Biotech, Aidenbach, 
Germany) containing 1% penicillin-streptomycin (PS; PAN- 
Biotech), placed on a petri dished, and finely minced with sterile 
scissors. The tissues were digested with 0.1% collagenase type 
ⅠA (Gibco/Life Technologies, Carlsbad, CA, USA) solution, and 
incubated for 1 hour at 37℃ in a humidified atmosphere of 
filtered 5% CO2. After digestion, high-glucose Dulbecco’s 
modified Eagle medium (DMEM; PAN-Biotech) with 10% fetal 
bovine serum (FBS; PAN-Biotech) and 1% PS was added to 
neutralize the sample. The sample was centrifuged at 1200 xg 
for 5 min.  The supernatant was discarded, the cell pellet was 
suspended in high-glucose DMEM, and the suspension was 
passed through a 70-㎛ Falcon cell strainer (Fisher Scientific, 
Waltham, MA, USA) to remove debris. The suspension was 
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centrifuged again at 1,200 xg for 5 min. Red blood cell lysis 
buffer (Sigma-Aldrich, St. Louis, MO, USA) was added and the 
cell solution was incubated for 10 min at 25℃ to remove 
erythrocytes. Cells were washed with five volumes of DPBS and 
centrifuged again. The supernatant was aspirated, and then the 
cells were resuspended in high-glucose DMEM and seeded 
(3,000/㎠) onto a 100 ㎜ ø cell culture dish. Unattached cells 
were removed the next day by washing with DPBS.
2.3. Harvest and isolation of canine bone-marrow- 
derived mesenchymal stem cells (cBM-MSCs)
Bone marrow samples were diluted with an equal volume 
of DPBS, and then gently layered over Ficoll-Paque PLUS (GE 
Healthcare Life Sciences, Uppsala, Sweden) in a conical tube. 
After centrifugation at 750 xg for 30 min, the buffy coat layer 
was carefully collected and centrifuged at 1200 xg for 10 min. 
The supernatant was discarded and the pellet was treated with 
red blood cell lysis buffer at room temperature for 15 min. 
DPBS was added and the suspension was centrifuged at 800 xg 
for 10 min. The supernatant was discarded, the cells were 
resuspended in alpha modified Eagle’s medium (αMEM; 
PAN-Biotech) as previously described (Karpov et al., 2013; 
Kisiel et al., 2012) then seeded as previously described for 
cAT-MSCs.
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2.4. Cell culture and expansion
The cAT- and cBM-MSCs were incubated at 37℃ in a 
humidified atmosphere of 5% CO2 in high-glucose DMEM 
(cAT-MSCs) or αMEM (cBM-MSCs) with 10% FBS and 1% 
PS. After 24 h, cultures were washed with DPBS to remove 
non-adherent cells and fresh medium was added. The culture 
medium was changed every 3 days until cells reached about 80% 
confluency. For all passages from P0 to P4, cultured cells were 
seeded at 10,000/㎠ in 100 ㎜ ø cell culture dishes and 
subcultured to 70–80% confluency using 1 ㎖ of 0.25% trypsin 
-EDTA (PAN-Biotech). All MSCs used in the experiment were 
in passage 3 or 4, as described in previous studies (Baksh et 
al., 2007; Kim et al., 2009; Lee et al., 2014).
The RAW 264.7 murine macrophage-like cell line was 
purchased from the Korean Cell Line Bank (Seoul, Korea). RAW 
264.7 cells were cultured in HDMEM containing 10% FBS and 
1% PS. Medium was replaced every 2–3 days until the cells 
reached 70–80% confluency. 
2.5. Characterization of MSCs
Canine MSCs were characterized by immunophenotyping 
and multilineage differentiation. For immunophenotyping, cells 
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were evaluated by flow cytometry for the expression of stem 
cell markers using antibodies conjugated with fluorescein 
isothiocyanate (FITC)-, phycoerythrin (PE)-, or allophycocyanin 
(APC). Antibodies were against cluster of differentiation (CD) 29 
(FITC), CD34 (PE), and CD73 (PE) (all from BD Biosciences, 
Franklin Lakes, NJ, USA); and against CD44 (FITC), CD45 
(FITC), and CD90 (APC) (all from eBiosciences, San Diego, CA, 
USA). The cells were sorted into defined populations using 
fluorescent-activated cell sorting (FACS) such that a pure 
population with the appropriate cell marker profile was produced. 
Results were analyzed by FlowJo 7.6.5 software (Tree Star, 
Inc., Ashland, OR, USA).
For cellular differentiation, cells were plated in 24-well 
plates and cultured in growth medium to 90% confluency prior to 
differentiation. The differentiation capacity of the cells was 
confirmed by identifying differentiated cells using special 
differentiation media (PRIME-XV Adipogenic Differentiation SFM, 
PRIME- XV Osteogenic Differentiation SFM and PRIME- XV 
Chondrogenic Differentiation XSFM; all from Irvine Scientific, 
Santa Ana, CA, USA), followed by Oil Red O staining, Alizarin 
Red staining, and Alcian Blue staining, respectively.
2.6. Canine peripheral blood mononuclear cell
(cPBMC) isolation
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Donor blood from a healthy canine was obtained from 
SNU VMTH and diluted with an equal volume of PBS, and then 
layered over Ficoll-Paque PLUS (GE Healthcare Life Sciences, 
Uppsala, Sweden) in a conical tube. After centrifugation at 850 
xg for 30 min, the buffy coat layer was carefully collected. The 
collected samples were incubated with RBC lysis buffer at 25℃ 
for 15 min. After PBS addition, samples were centrifuged at 750 
xg for 10 min. Washing and centrifugation were repeated. 
cPBMCs were resuspended in Roswell Park Memorial 
Institute-1640 medium (Pan-Biotech, Dorset, Germany) 
containing 10% FBS and 1% PS.
2.7. Preparation and of conditioned medium (CM)
The cAT-/cBM-MSCs (3 × 105 cells/well) were seeded 
in 6-well plates and cultured in αMEM medium containing 10% 
FBS and 1% PS for 3 days to yield conditioned medium 
(Timmers et al., 2011). After 6 hours, the cAT-/cBM-MSCs 
were stimulated with the pro-inflammatory cytokines TNF-α 
(20 ng/㎖; PROSPEC Protein Specialists, NJ, USA) and IFN-γ 
(20 ng/㎖; Kingfisher Biotech, MN, USA) for 24 h (English et 
al., 2007; Prasanna et al., 2010). Concentrations and times were 
chosen after optimization studies (data not shown). After 
stimulation, cells were washed 3 times with DPBS and cultured 
with αMEM. After 3 days, conditioned medium was harvested 
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and centrifuged at 850 rpm for 5 min to remove cellular debris. 
The supernatant was transferred to a conical tube and stored at 
-80℃.
2.8. Co-culture experiments
RAW 264.7 cells or cPBMCs were co-cultured with 
conditioned media of cAT- or cBM-MSCs. RAW 264.7 cells or 
cPBMCs were stimulated with lipopolysaccharide (LPS) (200 ng/
㎖; Sigma-Aldrich, St. Louis, MO, USA), and another population 
of unstimulated cells was used as a control. After incubation for 
24 h, stimulated and unstimulated RAW 264.7 cells or cPBMCs 
were washed with DPBS and seeded in 6-well plates (1 × 106 
cells/well) in triplicate. After the cells had adhered to the plate, 
the medium was suctioned off and replaced with the conditioned 
media from cAT- or cBM-MSCs, after which incubation 
continued for 3 days. 
2.9. RNA extraction, cDNA synthesis, and qRT-PCR
Total RNA from Raw 264.7 cell was extracted using the 
Easy-BLUE Total RNA Extraction kit (Intron Biotechnology, 
Sungnam, Korea). cDNAs were synthesized from 1 ㎍ of total 
RNA using the CellScript All-in-One 5X First Strand cDNA 
Synthesis Master Mix (CellSafe, Seoul, Korea). Samples were 
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evaluated in duplicate in 10 ㎕ AMPIGENE qPCR Green Mix 
Hi-ROX with SYBR Green dye (Enzo Life Sciences, Farmingdale, 
NY, USA) using 1 ㎕ cDNA and 400 nM each of forward and 
reverse primers (BIONICS, Seoul, Korea). Expression was 
normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH).
2.10. Western blot
Total protein from the MSCs was extracted using 
PRO-PREP Protein Extraction Solution (Intron Biotechnology). 
Protein concentration was measured using the Bio-Rad DC 
Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Proteins were 
separated by SDS PAGE and transferred to polyvinylidene 
difluoride membranes (Millipore, Billerica, MA, USA). The 
membranes were blocked (5% non-fat dry milk in Tris-buffered 
saline containing 0.1% Tween 20), then incubated with primary 
antibodies against COX-2 (1:500; Santa Cruz Biotechnology, 
Dallas, Texas, USA) at 4℃ overnight, followed by incubation 
with secondary antibodies for 1 h at room temperature. 
Immunoreactive bands were normalized to β-actin (1:1000; 
Santa Cruz) and visualized using enhanced chemiluminescence 
(Advansta, Menlo Park, CA, USA).
2.11. Enzyme-linked immunosorbent assay (ELISA)
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PGE2 was measured in cleared supernatants 
(centrifugation for 5 min at 850rpm) from treated or 
non-treated cAT-/cBM-MSCs using the canine PGE2 ELISA Kit 
(Cusabio Biotech, MD, USA).
2.12. Statistical Analysis
Data are expressed as mean ± SD. The statistical 
significance of the mean values was compared by one-way 
ANOVA and Student’s t test using the GraphPad Prism v.6.01 
software (GraphPad Software Inc., CA, USA). p-values < 0.05 
were considered to indicate statistical significance.
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3. Results
3.1. Characterization of cAT- and cBM-MSCs
Cells obtained from canine adipose tissue and from bone 
marrow were characterized by immunophenotyping and 
tri-lineage differentiation. Three to five days after seeding, 
spindle-shaped cells were adhered to the culture plates. The 
cells were positive for expression of CD29, CD44, CD73, CD90 
but did not express CD34 and CD45 (Fig. 1A and B). cAT- and 
cBM-MSCs were able to differentiate into adipocytes, 
osteocytes, and chondrocytes (Fig. 1C and D).
3.2. Enhanced anti-inflammatory effects of 
TNF-α- and IFN-γ- primed cAT- and 
cBM-MSCs
In order to determine the enhanced anti-inflammatory 
capacity of primed cAT- and cBM-MSCs, iNOS and several 
pro-inflammatory cytokines such as IL-1β and IL-6 were 
measured at the RNA level in LPS-stimulated RAW 264.7 cells. 
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IL-1β, IL-6 and iNOS expression levels of LPS-stimulated 
RAW 264.7 cells cultured with conditioned media (CM) of 
cAT-MSCs were significantly reduced compared with those of 
LPS-stimulated RAW 264.7 cells alone. Notably, expression 
levels of the inflammatory markers were reduced in the 
LPS-stimulated RAW 264.7 cells cultured with TNF-α/IFN-γ
-primed cAT-MSCs compared with those in LPS-stimulated 
RAW 264.7 cells cultured with naïve cAT-MSCs (Fig. 2). 
Furthermore, in the case of cBM-MSCs, all expression levels in 
LPS-stimulated RAW 264.7 cells were shown to be further 
reduced when cultured with CM of TNF-α/IFN-γ primed 
cBM-MSCs compared to co-culture with naïve cBM-MSCs (Fig. 
2).
I also measured pro-inflammatory cytokine levels in 
cPBMCs. iNOS and IL-6 expression levels of LPS-stimulated 
cPBMCs cultured with TNF-α/IFN-γ-primed CM of 
cAT-MSCs were both reduced compared to those in 
LPS-stimulated cPBMCs cultured with naïve cAT-MSCs. In 
addition, for cBM-MSCs, all expression levels in LPS-stimulated 
cPBMCs were further reduced when cultured with CM of TNF-
α/IFN-γ primed cBM-MSCs compared to in co-culture with 
naïve cBM-MSCs, and the difference for iNOS was significant. 
Although IL-6 showed a decreasing tendency, the difference 
was not significant (Fig. 3).
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3.3. Increased expression of COX-2/PGE2 in 
TNF-α/IFN-γ-primed cAT- and cBM-MSCs
Next, I measured the protein level of COX-2 from TNF-
α/IFN-γ-primed cAT- and cBM-MSCs, and from naïve cAT- 
and cBM-MSCs. The protein level of COX-2 in TNF-α/IFN-γ
-primed cAT-MSCs was 7.4 times higher than in naïve 
cAT-MSCs (Fig. 4A). Likewise, the protein level of COX-2 in 
TNF-α/IFN-γ-primed cBM-MSCs was 1.7 times greater than 
in naïve cBM-MSCs (Fig. 4B). Thus, a significant difference 
occurs in COX-2 levels between the TNF-α/IFN-γ-primed 
groups and the naïve groups in cAT- and in cBM-MSCs.
Based on the increased COX-2 level in TNF-α/IFN-γ
-primed cAT- and cBM-MSCs, I measured PGE2 production in 
these cells. Higher levels of PGE2 production were measured 
insupernatant of TNF-α/IFN-γ-primed cAT-MSCs than in 
supernatant of naïve cAT-MSCs (Fig. 5A). Likewise, higher 
levels of PGE2 production were measured in supernatant of 
TNF-α/IFN-γ-primed cBM-MSCs than in that of naïve 
cBM-MSCs (Fig. 5B).
3.4. Decreased anti-inflammatory effects of CM 
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with PGE2 inhibitor, NS-398
Next, I examined how the PGE2 inhibitor NS-398 (Enzo 
Life Sciences, Farmingdale, NY, USA) affected the 
immunoregulatory capacity of CM by measuring the level of 
iNOS in LPS-stimulated RAW 264.7 cells co-cultured with 
cAT-MSCs. The decrease in iNOS level seen in LPS-stimulated 
RAW 264.7 cells co-cultured with TNF-α/IFN-γ-primed 
cAT-MSCs was negated by NS-398 treatment (Fig. 6).
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4. Discussion
MSCs have been applied to treatment of various diseases. 
Recently, attention has focused on the application of MSCs to 
immune-mediated diseases (Aggarwal and Pittenger, 2005; Shi 
et al., 2010; Shi et al., 2012; Uccelli et al., 2007; Yagi et al., 
2010), and numerous attempts have been made to increase 
immunomodulation effects of MSCs (Barrachina et al., 2017; 
Chiesa et al., 2011; Das et al., 2009; Yu et al., 2013). It has 
been shown that MSCs primed with inflammatory cytokines 
enhance immune reactions in humans (Hemeda et al., 2010) and 
in mice (English et al., 2007). However, studies of canine MSCs 
are few. Accordingly, I evaluated immunomodulatory effects and 
mechanisms of canine MSCs treated with TNF-α and IFN-γ. I 
used mesenchymal stem cells derived from two different 
sources: adipose tissue and bone marrow.
In a preliminary experiment I found the optimal 
concentration of inflammatory cytokines for priming canine 
MSCs; the combination of TNF-α (20 ng/㎖) and IFN-γ (20 
ng/㎖) was most suitable (data not shown). IL-1β, IL-6 and 
iNOS expression levels of LPS-stimulated RAW 264.7 cells 
were significantly reduced in the TNF-α/IFN-γ-primed cAT 
and BM-MSC group compared to those in the naïve cAT- and 
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BM-MSC group (Fig. 2). Next, I used canine PBMCs to evaluate 
the anti-inflammatory effects of canine MSCs. iNOS expression 
levels in LPS-stimulated cPBMCs co-cultured with TNF-α
/IFN-γ-primed CM of cAT and BM-MSCs were significantly 
reduced compared to those in LPS-stimulated cPBMCs 
co-cultured with naïve cAT- and BM-MSCs. IL-6 levels tended 
to decrease in cPBMCs co-cultured with TNF-α/IFN-γ
-primed CM of cAT- and BM-MSCs compared to in cPBMCs 
co-cultured with naïve cAT- and BM-MSCs (Fig. 3). Taken 
together, I found that priming with TNF-α and IFN-γ 
enhanced the anti-inflammatory effects of cAT-MSCs and of 
cBM-MSCs.
It has been shown that MSCs regulate the inflammatory 
process through various soluble factors such as TSG-6 (Liu et 
al., 2016; Song et al., 2017), IDO (Spaggiari et al., 2008), TGF-
β (Liu et al., 2015), HGF (Puissant et al., 2005), and PGE2 
(Spaggiari et al., 2008). Among these, PGE2 has been identified 
as pivotal for the anti-inflammatory effects of MSCs (Solchaga 
and Zale, 2012; Manferdini et al., 2013). Similarly, COX-2 is an 
immunomodulatory factor secreted by MSCs (Kang et al., 2008; 
Carrade and Borjesson, 2013). Based on these previous findings, 
it is tempting to speculate that the COX-2/PGE2 pathway from 
cAT- and cBM-MSCs plays a key role in enhancing anti- 
inflammatory action. Indeed, our experiments showed the protein 
level of COX-2 from TNF-α/IFN-γ-primed cAT- and cBM- 
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MSCs to be significantly higher than that from a naïve 
population. In addition, PGE2 in TNF-α/IFN-γ-primed cAT- 
and cBM-MSCs was markedly higher than that in naïve cells. 
Therefore, I have shown that the increased the anti- 
inflammatory effects in TNF-α/IFN-γ-primed cAT- and 
cBM-MSCs are related to increased activation of the 
COX-2/PGE2 pathway.
I next asked whether PGE2 is involved in enhancing the 
anti-inflammatory effect of MSCs pretreated with TNF-α and 
IFN-γ by examining the effect of the PGE2 inhibitor NS-398 
on iNOS protein levels. The decreased iNOS level in 
LPS-stimulated RAW 264.7 cells co-cultured with TNF-α
/IFN-γ-primed cAT-MSCs was absent after NS-398 
treatment. Thus, the increase in PGE2 secretion of TNF-α/IFN-
γ-primed cAT-MSCs directly affected the anti-inflammatory 
action.
There were some limitations in our study. I obtained 
cAT- and cBM-MSCs from two dogs. Although these two MSC 
populations showed similar immunomodulatory effects, larger 
populations should be investigated. Studies on other 
immunomodulatory factors, together with in vivo applications, are 




In conclusion, this study revealed that TNF-α/IFN-γ
-primed canine MSCs more effectively reduced inflammation of 
activated RAW 264.7 cells than did naïve canine MSCs. In 
addition, I suggest that an increased COX-2/PGE2 pathway is 
one mechanism of enhanced immunomodulatory effects in TNF-
α/IFN-γ-primed canine MSCs. Furthermore, our study might 
provide insight into the application of TNF-α/IFN-γ-primed 
cAT- and cBM-MSCs for canine patients.
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Figure 1. Characteristics of MSCs isolated from canine adipose 
tissue and bone marrow. Immunophenotypic analysis by flow 
cytometry of canine-adipose-tissue-derived mesenchymal stem 
cells (A), and canine-bone-marrow-derived mesenchymal stem 
cells (B). Adipogenic (Oil Red O staining), osteogenic (Alizarin 
Red S staining), and chondrogenic (Alcian Blue staining) 
differentiation of cAT-MSCs (C), and cBM-MSCs (D).
22
 
Figure 2. Anti-inflammatory effects of primed cAT- and 
cBM-MSCs on LPS-stimulated RAW 264.7 cells. Effect of 
cAT-MSCs on anti-inflammatory cytokine levels. mRNA 
expression levels of iNOS, IL-1β, and IL-6 in RAW 264.7 cells 
(A). Effect of cBM-MSCs on anti-inflammatory cytokine levels. 
mRNA expression levels of iNOS, IL-1β, and IL-6 in RAW 
264.7 cells (B). Data are shown as mean ± SD. *P < 0.05, **P 
< 0.01, ***P < 0.001. (RAW 264.7 +: exist, LPS -: 
non-treated, LPS +: treated, cAT- and cBM-MSCs -: absence)
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Figure 3. Anti-inflammatory effects of primed cAT- and 
cBM-MSCs on LPS-stimulated cPBMCs. Effect of cAT-MSCs 
on anti-inflammatory cytokine levels. mRNA expression levels of 
iNOS and IL-6 in cPBMCs (A). Effect of cBM-MSCs on 
anti-inflammatory cytokine levels. mRNA expression levels of 
iNOS and IL-6 in cPBMCs (B). Data are shown as mean ± SD. 
*P < 0.05, **P < 0.01. (cPBMC +: exist, LPS -: non-treated, 
LPS +: treated, cAT- and cBM-MSCs -: absence)
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Figure 4. COX-2 protein level in TNF-α- and IFN-γ-primed 
cMSCs. The COX-2 level in TNF-α/IFN-γ-primed cAT- 
MSCs was 7.4 times higher than in naïve cAT-MSCs (A). 
Likewise, the COX-2 level in TNF-α/IFN-γ-primed 
cBM-MSCs was 1.7 times greater than in naïve cBM-MSCs (B). 
*P < 0.05, ***P < 0.001. (cAT- and cBM-MSCs +: exist, 
TNF-α+IFN-γ -: non-treated, TNF-α+IFN-γ +: treated)
  
25
Figure 5. Protein level of PGE2 in supernatant of TNF-α- and 
IFN-γ-primed cMSCs. Higher levels of PGE2 production were 
measured in supernatant of TNF-α/IFN-γ-primed cAT- (A) 
and cBM-MSCs (B) than in supernatants of naïve cAT- and 
cBM-MSCs. **P < 0.01. (cAT- and cBM-MSCs +: exist, TNF-
α+IFN-γ -: non-treated, TNF-α+IFN-γ +: treated)
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Figure 6. Changes in the secretion of PGE2 in NS-398-treated 
CM. Decreased the protein level of iNOS in LPS-stimulated 
RAW 264.7 cells co-culture with TNF-α/IFN-γ-primed canine 
AT-MSCs was increased again in the NS-398 treated group. *P 
< 0.05, ***P < 0.001. (LPS-stimulated RAW 264.7 +: exist, 
TNF-α+IFN-γ primed cAT-MSC -: absence, TNF-α+IFN-
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TNF-α 및 IFN-γ로 처리된 개 
중간엽줄기세포의 COX-2/PGE2 
경로를 통한 항염증 효과 향상
지도 교수: 윤 화 영
서울대학교 대학원
수의학과 수의내과학 전공
양  혜  미
중간엽줄기세포(Mesenchymal stem cells)는 다양한 질병의 
치료제로 연구되어 왔으며, 면역 매개 질환에 대한 응용 또한 관심을 끌
고있다. 사람의 중간엽줄기세포의 면역 조절 효과를 향상시키기위한 다
양한 방법이 사용되어왔으나, 개의 중간엽줄기세포에 대한 접근법은 연
구가 부족한 실정이었다. 따라서 본 학위 논문은 TNF-α 및 IFN-γ
로 처리된 개의 중간엽줄기세포에서 면역 조절 효과와 그 기전을 평가하
고자 하였다. TNF-α와 IFN-γ로 24시간 동안 개의 중간엽줄기세포
를 자극하여 적응용 배지(conditioned media)를 만들었다. 마우스의 면
38
역 세포(RAW 264.7)를 지질다당질(lipopolysaccharide, LPS)로 자극
하여, 적응용 배지에서 48시간 동안 개의 중간엽줄기세포와 함께 배양
하였다. 개의 면역 세포(cPBMC)로 동일하게 반복 실험하였다. 역전사 
중합효소 연쇄반응(qRT-PCR)에 의해 RNA의 발현을, 웨스턴 블롯
(Western blot) 분석을 통하여 단백질 수준에서 평가 하였다. LPS의 
자극을 받아 증가한 유도 산화질소 합성효소(iNOS), 인터루킨-6 및 인
터루킨-1β의 발현이 개의 중간엽줄기세포와 함께 배양하였을 때 통계
적으로(일원분산분석) 유의적으로 감소하였다(P < 0.001). 또한, 
TNF-α 및 IFN-γ 전처리된 개의 중간엽줄기세포와 처리되지 않은 
순수한 개의 중간엽줄기세포와 비교하였을 때 항염증 효과가 유의적으로 
증가됨을 확인하였다(P < 0.05). 다음으로, COX-2와 PGE2의 발현이 
전처리된 개의 중간엽줄기세포에서 유의하게 증가함을 확인하였다(P < 
0.05). 마지막으로, LPS에 자극 받은 RAW 264.7 세포에서 감소되었
던 iNOS 단백질의 양이 NS-398 (PGE2억제제)으로 처리하였을 때 재 
증가함을 확인하였다(P < 0.01). 본 연구는 TNF-α와 IFN-γ로 전처
리된 개의 중간엽줄기세포에서 처리되지 않은 순수한 개의 중간엽줄기세
포와 비교하였을 때, LPS로 자극된 세포에서 방출되는 항염증성 사이토
카인이 보다 더 감소하며, 그 기전 중 하나로 COX-2/PGE2경로가 관여
함을 과학적으로 알아낸 중요한 결과로 임상적으로 개 환자의 치료에 효
과적으로 적용할 수 있을 것으로 기대된다. 
주요어: 중간엽줄기세포; 염증 사이토카인; COX-2; PGE2; 항염증
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